Compare EDD & ANGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EDD | ANGO |
|---|---|---|
| Founded | 2007 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.1M | 420.2M |
| IPO Year | N/A | 2004 |
| Metric | EDD | ANGO |
|---|---|---|
| Price | $5.77 | $13.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 594.6K | 536.0K |
| Earning Date | 01-01-0001 | 04-02-2026 |
| Dividend Yield | ★ 7.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $291,010,000.00 |
| Revenue This Year | N/A | $9.51 |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.17 |
| 52 Week Low | $4.96 | $8.36 |
| 52 Week High | $6.18 | $15.20 |
| Indicator | EDD | ANGO |
|---|---|---|
| Relative Strength Index (RSI) | 49.96 | 54.96 |
| Support Level | $5.72 | $13.02 |
| Resistance Level | $6.03 | $13.76 |
| Average True Range (ATR) | 0.10 | 0.67 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 28.99 | 42.29 |
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.